June 29, 2020 / 12:14 PM / 9 days ago

BRIEF-PTC Therapeutics Announces CHMP Recommendation Of Translarna™ (Ataluren) Label Update For Non-Ambulatory Patients With Duchenne Muscular Dystrophy

June 29 (Reuters) - PTC Therapeutics Inc:

* PTC THERAPEUTICS ANNOUNCES CHMP RECOMMENDATION OF TRANSLARNA™ (ATALUREN) LABEL UPDATE FOR NON-AMBULATORY PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below